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Malignant melanoma (MM), the most common cause of skin cancer deaths, metastasises to regional lymph nodes. In animal models of
other cancers, lymphatic growth is associated with metastasis. To assess if lymphatic density (LD) was increased in human MM, and its
association with metastasis, we measured LD inside and around archival MM samples (MM, n¼21), and compared them with normal
dermis (n¼11), basal cell carcinoma (BCC, n¼6) and Merkel cell carcinoma (MCC), a skin tumour thought to metastasise through a
vascular route (MCC, n¼6). Lymphatic capillary density (mm
 2), as determined by immunohistochemical staining with the lymphatic
specific marker LYVE-1, was significantly increased around MM (10.072.5mm
 2) compared with normal dermis (2.470.9mm
 2),
BCC (3.070.9mm
 2) and MCC (2.471.4mm
 2)( Po0.0001). There was a small decrease in LD inside MM (1.170.7mm
 2)
compared with normal dermis, but a highly significant decrease in BCC (0.1470.13) and MCC (0.1272.4) (Po0.01 Kruskal–Wallis).
Astonishingly, LD discriminated between melanomas that subsequently metastasised (12.871.6mm
 2) and those that did not
(5.471.1mm
 2, Po0.01, Mann–Whitney). Lymphatic invasion by tumour cells was seen mainly in MM that metastasised (70%
compared with 12% not metastasising, Po0.05 Fisher’s Exact test). The results show that LD was increased around MMs, and that LD
and tumour cell invasion of lymphatics may help to predict metastasis. To this end, a prognostic index was calculated using LD,
lymphatic invasion and thickness that clearly discriminated metastatic from nonmetastatic tumours.
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Malignant melanoma (MM) results in 1600 deaths each year in the
UK, due to metastatic spread of the disease (Cancer Research UK,
2002). The most common site of metastatic disease in melanoma is
the regional lymph nodes. Currently, tumour thickness is the most
reliable prognostic factor and predictor of recurrence for primary
cutaneous melanoma. Melanomas are therefore commonly re-
ferred to as thin (o1.0mm thick), intermediate (1.0–4.0mm ) and
thick (44.0mm). Overall, 10-year survival probabilities for node-
negative patients range from 485% for thin melanomas to p45%
for thick melanomas (Stadelmann et al, 1998). Metastatic spread to
the lymph nodes dramatically reduces the overall survival rate at
10 years to 35% (White et al, 2002b) and by the time regional nodal
metastases are clinically obvious, 70–85% of patients have other
distant metastases. A significant proportion (15%) of patients with
thin tumours (o1mm) go on to develop metastatic disease and
there are currently no prognostic indicators for which patients
with thin MMs will develop metastasis.
Since most melanomas metastasise to the lymph nodes, it has
been postulated for many years that they spread through the
lymphatic system (Elias et al, 1977). It is not clear, however,
whether (a) the malignant cells migrate into the intratumoral
lymphatics once the tumour has grown to enclose pre-existing
lymphatics; (b) the melanoma cells stimulate lymphatic growth
into or around the tumour; or (c) malignant cells migrate out of
the tumour mass and invade pre-existing lymphatics in the normal
tissue on the periphery of the tumour. Recent work in animal
models showed that the incidence of metastasis is increased in
tumours expressing endothelial growth factors such as vascular
endothelial growth factor C (VEGF-C) (Skobe et al, 2001b) and
VEGF-D (Stacker et al, 2001). Furthermore, VEGF-C expression,
driven by the rat insulin promoter, resulted in the development of
b-cell tumours surrounded by an extensive lymphatic network, in
which tumour cell masses were observed. These mice also had an
increased rate of lymph node metastasis (Mandriota et al, 2001).
These studies have led to the hypothesis that tumours that
stimulate lymphangiogenesis or angiogenesis will be more likely to
metastasise than tumours that do not. This should result in more
vessels surrounding tumours that metastasise. Furthermore,
several recent reports have suggested that tumour derived
expression of VEGF-C and VEGF-D may have prognostic value
as indicators of metastatic spread in some prevalent human
cancers (White et al, 2002a; Kishimoto et al, 2003; Nakamura et al,
2003a,b; Schietroma et al, 2003; Yokoyama et al, 2003). The
density of blood vessels surrounding melanoma correlates poorly,
however, with tumour growth and metastasis (Foss et al, 1996;
Straume et al, 1999), despite the link between VEGF-A expression
and tumour progression (Erhard et al, 1996). The number of
lymphatic vessels associated with MM has not previously been
clearly identified. There have been some attempts to do this by
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ydifferential staining of basement membrane (de Waal et al, 1997;
Fallowfield and Cook, 1990), but neither of these showed any
change in the density of basement membrane-free vessels
(assumed to be lymphatics). The lack of lymphatic specific
markers, however, has prevented the clear identification of
surrounding lymph vessels or in tumours.
We have tested the hypothesis that lymphangiogenesis favours
nodal metastasis by comparing three different tumours with
differing patterns of metastasis, namely MM, Merkel cell
carcinoma (MCC) and basal cell carcinoma (BCC). Since BCC
does not metastasise, we hypothesised that LD will be low in and
around BCC, whereas it should be high around the readily
metastasising MM. Merkel cell carcinoma is a highly aggressive,
invasive and usually metastasising tumour that often presents with
distant metastasis even in the absence of lymph node involvement.
It metastasises to the lymph nodes in approximately half the
presenting patients, 69% of whom die within the first 3 years
(Medina-Franco et al, 2001), but the tendency to metastasise to
occult regions suggests that MCC is able to metastasise by a
vascular rather than a lymphatic route. We hypothesised therefore
that LD will be low in and around MCC as well as BCC.
The inability to distinguish lymphatics from blood vessels has
been a limiting factor in the assessment of lymphatic involvement
in tumours. Over the last 3 years, an increasing number of
lymphatic specific molecules have been identified (Podgrabinska
et al, 2002). One of the first of these was the lymphatic hyaluronan
receptor, LYVE-1 (Banerji et al, 1999). This has been shown to be
expressed almost exclusively on lymphatic endothelium, and
antibodies to LYVE-1 have been used to identify lymphatics in
and around normal skin (Banerji et al, 1999), cornea (Cursiefen
et al, 2002) head and neck (Beasley et al, 2002) and breast
cancers(Mattila et al, 2002). LYVE-1 is expressed on lymphatics in
all tissues so far investigated, and also on blood liver sinusoids
(Mouta Carreira et al, 2001). In the skin, however, staining appears
to be exclusive to the lymphatic endothelial cells. We have
therefore used this novel and specific marker to investigate
lymphatic densities in skin tumours.
METHODS AND MATERIALS
Materials
Rabbit anti-human LYVE-1 was a generous gift from Dr David
Jackson, Oxford, UK; Antibodies to PECAM-1 (sc-1506) VEGFR-3
(sc-321), and VEGF-C (sc-7133) were purchased from Santa Cruz
Biotechnology (Santa Cruz, USA), VEGF-D (AF286) from R&D
Systems and Ki-67 (NA59) from Oncogene.
Patient details
Control skin was collected from the breast of six patients
undergoing breast reduction surgery (total n¼11) at Frenchay
Hospital, Bristol, with Local Ethics Committee approval (North
Bristol NHS Trust). In total, 21 MM samples, six BCC samples and
six MCC samples were fixed at the time of excision and embedded
in paraffin. All tumour samples were archived tissue stored as
paraffin-embedded blocks. There were no significant differences
between follow-up times for metastatic and nonmetastatic
melanoma (time between excision of the tumour and the analysis
of the lymphatic densities) (mean7s.e.m.; 5.771.4 years, meta-
static, 8.371.5 years, nonmetastatic, P40.1 t-test). The thick-
nesses (3.470.8mm metastatic, 2.370.6mm nonmetastatic) were
also not significantly different (P40.1, t-test).
Assessment of metastasis
Patients were seen every 3–6 months from the time of excision,
depending on the thickness of the melanoma. Of the 21 MM
patients, 13 had subsequently developed metastasis diagnosed
according to the normal clinical practice, and eight were still free
of any form of clinically detectable spread. Only two of the patients
had died since the melanoma was originally removed, both from
metastasis.
Immunohistochemistry
Serial sections of paraffin-embedded melanoma samples were cut,
dewaxed and rehydrated prior to microwave antigen retrieval
(800w) in tris/EDTA (Trizma, 100mM; EDTA, 2mM), pH 9 for
8min. Endogenous peroxidase activity was blocked by incubation
for 5min in 3% hydrogen peroxide followed by two phosphate-
buffered saline (PBS) washes (PBS (mM): NaCl, 137; KCl, 2.68;
Na2HPO4, 10; KH2PO4, 1.76). Nonspecific binding was prevented
by incubation in normal serum for 20min in a humid chamber (for
LYVE-1, 5% human serum wv
 1 in PBS; for PECAM-1, VEGF-C,
VEGF-D and Ki67, 1.5% vv
 1 horse serum in PBS and for
VEGFR-3, 1.5%vv
 1 goat serum in PBS). Slides were incubated in
antibodies to LYVE-1 (4.2mgml
 1), PECAM 1 (8mgml
 1), VEGF-C
(1.14mgml
 1), VEGF-D (10mgml
 1), VEGFR-3 (2mgml
 1) or Ki67
(4mgml
 1), or normal rabbit IgG, goat IgG or mouse IgG at the
appropriate concentration, overnight at 41C. The slides were
washed twice (PBS/Tween, 0.05% vv
 1) and the nonimmune block
was repeated. The primary antibody was detected with a
biotinylated goat anti-rabbit (LYVE-1, VEGFR-3), horse anti-goat
(PECAM-1, VEGF-C, VEGF-D) or horse anti-mouse (Ki-67)
secondary antibody for 30min at room temperature. Following
two washes, slides were incubated in standard avidin biotin
complex (elite ABC kit for VEGF-C) for 30min at room
temperature, washed twice, visualised using DAB, rinsed in
distilled water and counterstaining with haematoxylin. Sections
were dehydrated and mounted in DPX. The results depend on
identification of the lymphatic specific marker, LYVE-1. Although
expressed on liver sinusoids (Mouta Carreira et al, 2001), LYVE-1
was found to be lymphatic specific in skin and preferential to other
markers of lymphatics such as VEGFR-3. LYVE-1, rather than
VEGFR-3, was used to count lymphatics because, although
VEGFR-3 was clearly expressed on lymphatic endothelial cells, it
was also detected on blood vessels, some tumour cells and basal
keratinocytes (data not shown).
Lymphatic vessel density
Samples were analysed using a Nikon E-400 microscope using a
 40 objective. A ‘lymphatic’ was identified as a structure with
LYVE-1-positive staining. The numbers of lymphatics found
within a tumour were counted by eye and images recorded with
a digital camera (coolpix 995; Nikon). A composite image was
generated from the images and used to calculate the tumour and
tissue area so that internal and external lymphatic densities could
be calculated, respectively. All vessel counts were performed by
one observer and lymphatic vessel density (LD) was calculated
without knowledge of clinical data or prognostic outcome. LD was
calculated as the number of lymphatic profiles per mm
2 of section.
Epitumoral LD was calculated as the LD within 350mm of the
tumour edge (1 field of view). The median area examined was
2.2mm
2 epitumoral and 3.7mm
2 intratumoral in the MM samples.
The median areas in the BCC and MCC samples were 2 and 5mm
2,
respectively, intratumoral and 4.5 and 4.4mm
2 epitumoral;
12.3mm
2 of normal dermis was examined. Images were analysed
using image analysis software NIH Image 1.62 to determine the
area fraction of lymphatics, that is the area of the lymphatic per
unit area of tissue.
Invasion of tumour cells into the lymphatics (lymphatic
invasion) in a given tumour was considered to be present if
tumour cells could be seen within any one LYVE-1 positive profile
in the entire field. Invasion of blood capillaries and venules
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y(vascular invasion) was considered to be present in a given tumour
if tumour cells could be seen within any one LYVE-1 negative,
PECAM-1-positive vessel within the tumour.
Statistical analysis
The results are presented as a mean7s.e.m. Differences between
lymphatic density and area fraction in tumour samples were
analysed by Kruskal–Wallis test, a nonparametric one-way
analysis of variance (ANOVA), followed by Dunn’s post hoc test
for multiple comparisons, and with Mann–Whitney U-test for
single comparisons. To determine whether epi- and intratumoral
LD or area fraction was different between metastatic and
nonmetastatic, and vice versa, a two-way ANOVA and Bonferroni
post hoc test was used. To determine significant differences of
frequency of lymphatic and vascular invasion, Fisher’s Exact test
was used. Po0.05 was considered significant.
RESULTS
Epitumoral LD
One-way ANOVA revealed significant differences in epitumoral LD
(LD in the 350mm border around the three types of tumour) and
the control dermis (Po0.0001, Figure 1). Epitumoral LD around
MMs (10.072.5mm
 2, n¼21) was approximately four times
higher than LD in the control dermis (2.470.9mm
 2, n¼11,
Po0.01 Dunn’s multiple comparison test) and 43 times higher
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Figure 1 Lymphatic density in normal dermis, intra-tumoural LD and dermis immediately around three types of skin cancer. (A) Lymphatic density inside
the tumour (green) was always lower than that outside the tumour (red). There was a significant increase in LD around the tumour in MM compared with
normal dermis, BCC and MCC. See Results for values and detailed statistical analysis. Lymphatic capillaries in dermis stained with LYVE-1 antibody (arrows)
in normal (B), BCC (C), MM (D) and MCC (E). Lymphatic vessels stained inside tumours in BCC (F), melanoma (G) and MCC (H). Inset is negative
control staining. Bar: (B–G),5 0mm; (H), 100mm.
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ythan epitumoral LD around BCC (3.070.9mm
 2, n¼6, Po0.05
Dunn’s test) or MCC( 2.471.4mm
 2, n¼6,Po0.05 Dunn’s test).
The epitumoral LD around BCC and MCC were not significantly
different from each other or from control LD (P40.05, Dunn’s
test).
Intratumoral LD
With regard to LD inside the tumours, one-way ANOVA again
revealed significant differences in intratumoral LD among the
three types of tumour and control dermis (Po0.01, Kruskal–
Wallis test) (Figure 1). The intratumoral LD in the MMs
(1.170.7mm
 2) was approximately eight times higher than
intratumoral LD in BCC (0.1470.19mm
 2) or MCC
(0.1270.16mm
 2), but not significantly lower than LD in the
control dermis (2.470.9mm
 2). Intratumoral LD inside the BCC
and MCC were both greatly reduced compared with the normal
dermis (Po0.01, Dunn’s post hoc test).
Epi- vs intratumoral LD
Two-way ANOVA showed that intratumoral LD was significantly
lower for both metastatic and nonmetastatic tumours (Po0.01,
metastatic, Po0.05 nonmetastatic, Figure 2A) than epitumoral LD,
but there was no difference between epi- and intratumoral LD of
the tumours in BCC or MCC (P40.05). As above, this was also true
for the lymphatic area fraction in metastatic MM (Po0.001), but
not in any other tumour type.
LD of metastasising versus nonmetastasising MM
Epitumoral LD around the MMs was more than twice as great in
patients who subsequently developed metastases (LD¼12.87
1.6mm
 2, n¼13, Figure 2A), than in those who had not yet
developed metastasis at the time of writing (LD¼5.471.1mm
 2,
n¼8) (Po0.01, Mann–Whitney U-test, and Po0.001 two-way
ANOVA, Figure 2A). Although the intratumoral LD was likewise
more than twice as great in the metastatic cases (LD¼1.47
0.6mm
 2 as in the currently nonmetastatic cases (0.670.3mm
 2),
this was not statistically significant. Although the thickness of an
MM is prognostic in general, there was no relationship between
thickness and LD in these patients (r¼ 0.26, P40.1, Spearman
rank correlation coefficient) (Figure 2B).
Lymphatic area fraction
Lymphatic area fraction, calculated as the total intratumoral
lymphatic area as a fraction of the entire area, was also increased in
melanoma compared with normal, BCC and MCC and greater in
metastatic melanoma than in nonmetastatic melanoma (see
Table 1). These results are similar to the LD results. There were
no significant differences between the average size of the
lymphatics (lymphatic area divided by the LD) between any of
the tumours and normal tissue outside the tumours (P¼0.46, one-
way ANOVA, all mean7s.e.m. in mm
2, 0.08270.044MM,
0.07670.044 metastatic MM, 0.09170.046 nonmetastatic MM;
0.05570.039 BCC, 0.06570.021 MCC, 0.04570.005 normal).
Vascular and lymphatic invasion
Identification of the lymphatics in the tumour enabled vascular
invasion to be distinguished from lymphatic invasion. In both the
MM and MCC, vascular and lymphatic invasion were seen (Figure
3A–D). In the six MCC, vascular invasion was more common
(100% of tumours) than lymphatic invasion (33% of tumours,
Po0.01, Fisher’s Exact test). By contrast, there was no difference
between lymphatic (47.2%) and vascular invasion (42.9%) in the
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Figure 2 Relation between LD and metastasis in MM. (A) Lymphatic
density outside (solid bars, mean7s.e.m.) and inside (stippled bars) MM
classified according to whether the tumour had subsequently metastasised
(Po0.001, two-way ANOVA). Post hoc tests showed significant difference
between metastatic and nonmetastatic epitumoral LD (Po0.01, Mann–
Whitney U), and between epi- and intratumoral LD for both nonmetastatic
(Po0.05) and metastatic (Po0.001, Bonferroni), but not between
metastatic and nonmetastatic intratumoral LD. (B) Plot of LD against
thickness for nonmetastatic (open squares) and metastatic (filled diamonds)
melanoma. There was no significant correlation for the pooled group
(r¼ 0.2, P40.1).
Table 1 Lymphatic densities and area fractions in normal, BCC, MCC and MM
Lymphatic density (mm
 2) Lymphatic area fraction (%)
Mean7s.e.m.
2.570.5 0.11970.003
b
N
Normal Intratumoral Epitumoral Intratumoral Epitumoral 11
BCC 0.1470.19
a,b 3.070.9
b,c 0.00670.004
a,b 0.12370.021
a 6
MCC 0.1270.16
a,b 2.471.4
b,c 0.01870.015
a,b 0.15870.089
a 6
MM 1.170.7 10.072.5
c,d 0.03570.018
a 0.76070.304
d 21
Nonmetastatic MM 0.6470.29 5.471.1
c 0.02170.011 0.39970.044 8
Metastatic MM 1.470.6 12.871.6
c,d,e 0.04370.013 0.98270.244
d,c,e 13
aSmaller than normal.
bSmaller than MM.
cGreater than intratumoral.
dGreater than normal.
eGreater than nonmetastatic.
Lymphatic density and metastasis in melanoma
JD Shields et al
696
British Journal of Cancer (2004) 90(3), 693–700 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ymelanoma samples (P¼1.0, Fisher’s Exact test) (Figure 3E). The
combination of both lymphatic and vascular invasion in the same
specimen was seen frequently in the metastasising melanomas
(46%), but the combination did not occur in any of the
nonmetastatic tumours (Po0.05 w
2 test). Therefore, although not
all metastatic melanomas showed lymphatic invasion (Figure 3F),
all the melanomas that showed both lymphatic and vascular
invasion were metastatic. In the four metastatic melanomas
without detectable lymphatic invasion, the LD (11.372.1mm
 2,
n¼4) was significantly greater than LD in those that had not
metastasised (5.471.1mm
 2, n¼11; Po0.05, state test used).
There was no significant difference between the lymphatic
densities of metastasised melanomas with (1.570.83mm
 2
intratumoral 13.572.21mm
 2 epitumoral) or without lymphatic
invasion (1.1570.42mm
 2 intratumoral 11.2572.11mm
 2 epitu-
moral).
Tumour thickness
There were no differences in the lymphatic densities between thin,
medium or thick melanomas either inside or on the outside of the
tumour (see Table 2), and in this sample the prognostic value of
thickness was negligible (metastatic 3.3670. 76mm, nonmetastatic
2.2870.72mm, P¼0.3, t test)
Site and ulceration
There were no differences in the epitumoral lymphatic vessel
densities between melanomas with either lymph node metastasis
or metastasis to other sites (lymph node 11.171. 2mm
 2, other
16.674.36mm
 2, P¼0.2 Mann–Whitney U-test), or between
melanomas with or without ulceration (ulcerated
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Figure 3 Lymphatic and vascular invasion in MM. Tumour cells were seen inside lymphatic capillaries (positive for LYVE-1) in both MM (A) and MCC (B).
Vascular invasion (tumour cells inside PECAM positive, LYVE-1 negative vessels) was also seen in MM (C) and MCC (D). (E) Frequency of vascular (black)
and lymphatic (stippled) invasion in MM and MCC. Although lymphatic and vascular invasion were equally common in MM, vascular invasion was significantly
more common than lymphatic invasion in MCC Po0.05, Fisher’s exact test. (F) Invasion frequency observed in metastatic (red) and nonmetastatic
melanomas (blue). Lymphatic invasion alone, vascular invasion alone and both lymphatic and vascular invasion were significantly more common in metastatic
than nonmetastatic melanomas. Combined vascular and lymphatic invasion was a particularly strong prognostic sign for metastasis (although not significantly
different from either alone). Invasion of neither lymphatic nor vascular microvessels indicated a favourable prognosis, that is, no metastasis. Bar( A, C, D),
50mm; (B), 100mm.
Table 2 Lymphatic densities of thick, intermediate and thin tumours
Thickness (mm) Intratumoral LD (mm
 2) Epitumoral LD (mm
 2)
o1 1.1370.29 10.5172.20
1–4 2.0971.00 12.3672.69
44 0.1870.07 7.5171.97
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 2, nonulcerated 13.172.4mm
 2, P¼0.92 Mann–
Whitney U-test). Of the metastatic melanoma samples, 69%
presented with lymph node involvement, 61.5% were nonulcer-
ated, 23.1% were ulcerated and the status of 15.4% was unknown.
Lymphatic endothelial proliferation and lymphangiogenic
growth factors
Serial sections from all samples were taken and stained for
proliferating lymphatic endothelial cells using successive LYVE-1
and Ki-67 staining. No staining was seen in any lymphatics. There
was no clear evidence supporting the presence of proliferating
lymphatics either within or around the melanomas, despite clear
staining of the tumour tissue. VEGF-C and VEGF-D immunostain-
ing was apparent in melanoma samples, but there were no
qualitative differences in the intensity of staining for VEGF-C or
VEGF-D in metastatic versus nonmetastatic melanoma samples.
DISCUSSION
The mechanism through which MM spreads to the lymph nodes is
key to understanding and preventing metastasis. Previous work in
animal models has shown that overexpression of the lymphatic
growth factor VEGF-C in breast cancer cells or beta cell tumours of
the pancreas stimulates metastasis (Skobe et al, 2001b; Mandriota
et al, 2001). The evidence is conflicting, however, on the role of
lymphatics in human MM metastasis (Clarijs et al, 2001). Human
MM in situ expresses VEGF-C (Salven et al, 1998), but direct
evidence for lymphangiogenesis into the melanomas is lacking.
Recently, however, overexpression of VEGF-C had been shown to
stimulate lymphangiogenesis in xenotransplanted human melano-
mas (Skobe et al, 2001a), and in the chick chorioallantoic
membrane, and this occurs through activation of VEGF receptor
3 (flt-4) in lymphatic endothelial cells (Papoutsi et al, 2000).
Vascular endothelial growth factor D, another lymphangiogenic
growth factor, has also been shown to be upregulated in melanoma
and other tumours (Achen et al, 2001) (Yokoyama et al, 2003).
Vascular endothelial growth factor C and -D staining were
apparent in these samples, but there were no qualitative
differences in the intensity of staining for VEGF-C or VEGF-D in
metastatic vs nonmetastatic melanoma samples, as has been
reported in other small-scale studies (Dadras et al, 2003). This is
consistent with VEGF-C and -D not showing prognostic signifi-
cance in melanoma compared to other tumours such as oral,
breast or ovarian carcinoma (Kishimoto et al, 2003; Nakamura
et al, 2003a, b; Yokoyama et al, 2003).
There are a number of possible interpretations for the new
findings presented in this study. The intratumoral LD in the MM
was lower than LD in control dermis, but greater than in BCC or
MCC. This might be due in principle either to the incorporation of
some, but not all pre-existing lymphatics as the tumour invades
the surrounding tissue, or due to the stimulation of vessel growth
in an initially alymphatic tumour mass. Intratumoral LD was
reduced almost to zero in BCC (a noninvasive, nonmetastasising
tumour) and MCC (an invasive, distantly metastasising tumour).
The intratumoral LD in the MM is closer to normal. Therefore,
either some lymphatics must have been co-opted from normal
tissue – a process that clearly does not happen in MCC or BCC, or
lymphangiogenesis into the tumour must have occurred. The
increase in epitumoral LD could be due to the tumour growing as a
discrete entity and compacting the surrounding areas (hence
increasing LD), or due to lymphangiogenesis, but again a
comparison of MM with MCC and BCC supports the latter
mechanism in MM. Another possibility – that MMs always grow in
areas of skin containing a high LD – is not borne out by many
decades of research into the relation between the site of the
melanoma and the incidence of metastasis. There is no evidence of
a relationship between the incidence of metastasis and sites with
high LD (e.g. melanoma on the breast). The most likely
explanation, therefore, for increased epi and intratumoral LD is
that this particular tumour provides a particularly powerful
lymphangiogenic stimulus.
Interestingly, there was a significantly greater LD around the
melanomas than inside them, but the average size (cross-sectional
area) of the lymphatics was not different. Since interstitial pressure
is significantly higher inside the tumour than outside (Curti et al,
1993), and tumour vasculature is relatively leaky to fluid and
solutes (Yuan et al, 1996), this would suggest that the majority of
fluid cleared from the tumour goes through epitumoral lymphatics
rather than intratumoral ones. This supports experiments that
have shown a flow of fluid from the centre to the periphery of
tumours, which may interfere with drug delivery to these tumours
(Baxter and Jain, 1989). These results, however, do not provide
evidence for or against the hypothesis that lymphatics inside
tumours are not functional (Padera et al, 2002).
In this small study, there was no evidence of lymphatic
proliferation at the time of excision. Therefore, active lymphan-
giogenesis could not be detected immunohistochemically. This
neither confirms nor denies that lymphangiogenesis has occurred
since the increase in LD must have occurred while the tumour was
growing prior to excision and the newly formed tumour-
stimulated lymphatics may be in a mature rather than in a
proliferative state.
There has recently been one report that LD may be decreased in
patients with metastasis, in contrast to the results shown here
(Straume et al, 2003) and a second, very recently published, which
supports the data described here (Dadras et al, 2003). The major
difference between the current study and that of both Straume et al
and Dadras et al was that we have determined the absolute LD
around the melanoma by counting all the vessels, whereas both the
other studies determined only the LD of the ‘‘hot spots’’ of
lymphatics surrounding the melanoma. Straume et al found that
the LD of the ‘‘hot spots’’ was reduced, and Dadras et al found that
it was increased in samples from patients that developed
metastasis. The difficulty with these findings is the subjective
nature of the ‘‘hot spot’’. A "hot spot" is an area of particularly high
density of blood vessels as defined by Weidner et al (1991). Since
this description, a few studies have used "hot spots" to quantitate
lymphatic as well as vascular microvessel density in prevalent
cancers other than melanoma (Birner et al, 2001; Maula et al,
2003). Hot spots, however, are representative of localised
"biologically important" areas. This is more applicable to the
growth of microvascular capillaries in response to the local release
of growth factors stimulated by localised changes in oxygen
tension. In addition, several reviews have outlined the difficulties
with this technique, namely the subjective nature of the method;
there is no defined cutoff point, and the influence of the measured
area. Each of these variables leads to discrepancies between studies
(Fox et al, 1995; Vermeulen et al, 2002). Since lymphatic growth
does not appear to be regulated by hypoxia, there is no reason to
assume that a functional increase in lymphatics will occur in "hot
spots". Therefore, absolute LD may be a more appropriate and
easily standardised measurement.
Prognostic information
Tumour thickness is currently the most reliable predictor of
recurrence for primary cutaneous melanoma and the single most
important prognostic factor (Stadelmann et al, 1998). There is
currently no consensus on the frequency of follow-up or
recommendations for surveillance testing for all patients with
melanoma, since at present there is no effective method to identify
the small subgroup of patients with thin but aggressive MM. It
would be helpful, therefore, to find a prognostic indicator to detect
the high-risk patients in the group of ‘‘thin melanoma’’ (29% of the
Lymphatic density and metastasis in melanoma
JD Shields et al
698
British Journal of Cancer (2004) 90(3), 693–700 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ycases in this study). Since metastatic spread correlated with LD,
even in thin melanomas (Figure 2), these results indicate that
patients whose biopsy has a high LYVE-1 count could be included
in a more intensive follow-up schedule, or considered for adjuvant
treatment, even if the MM is thin. Furthermore, it may be possible,
using LYVE-1 immunohistochemistry, to identify which of the
thicker melanomas are not going to metastasise.
Prognostic index
Although thickness is a well-known prognostic factor, there are
many cases of thin melanomas becoming metastatic, and many
more of thick ones never metastasising. It would be useful,
therefore, to increase the efficiency of prognosis by using LD and
lymphatic invasion as prognostic factors. In this small study, LD
correlated more closely with MM metastasis than did thickness. In
order to determine whether, in this limited set of melanomas, there
was any way of combining information on thickness, LD and
lymphatic invasion, we calculated an index using all three terms,
but weighted for LD rather than thickness. A prognostic index (PI)
was calculated as the product of the LD squared (to weight the LD,
since it appeared a better prognostic indicator than either
lymphatic invasion or thickness), the thickness and a weighting
number for lymphatic invasion (2 if present in a single LYVE-
positive profile of the biopsy, 1 if not). Figure 4 shows PI for the
each MM studied, grouped according to whether the MM had
subsequently metastasised. In this, relatively small sample, PI
discriminated between those tumours that have subsequently
metastasised and those that have not done so after at least 6 years.
The highest PI in nonmetastatic MM was 110 and the lowest PI in
metastasising MM was 128, a 16% discrimination (see Figure 4).
On the basis of the present, admittedly limited results, a putative
prognostic index can be calculated that appears in this limited
sample to be deterministic, thus PI appears to merit a larger multi-
centre study. Further work is required to refine this PI, to further
evaluate the lack of correlation between thickness and metastasis
seen in this small study and to evaluate the incidence of false-
negative and false-positive predictions.
In summary, we show here that the LD in the dermis
surrounding MM is a good predictor of metastasis. The increased
LD is probably brought about by lymphangiogenesis, which in
turn supports the dissemination of cancer cells into the lymphatic
system. A larger scale study of LD around MMs might be of value
to determine the relative risk of metastasis with increased LD.
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